Aflibercept biosimilar is under clinical development by Alvotech and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Aflibercept biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aflibercept biosimilar overview
Alvotech overview
Alvotech is a biopharmaceutical company that develops, manufactures and commercializes biosimilar medicines. The company’s pipeline immunology products include AVT02, AVT04, AVT05, AVT16 and AVT23 target respiratory diseases; AVT06 and AVT33 for ophthalmology and oncology; AVT03 for bone disease; AVT19, AVT28 and AVT41. Its biosimilars include HUMIRA, STELARA, XOLAIR, PROLIA, SIMPONI, ARIA, EYLEA, ENTYVIO and KEYTRUDA. The company operates in the US, Luxemburg, Switzerland, Canada and Australia, among others. Alvotech is headquartered in Luxemburg.
For a complete picture of Aflibercept biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.